Research

Hormonal

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

ModerateQualifiesMEDIUM confidence
With a 70-year safety record in treating infectious diarrhea in China and preclinical evidence of multi-target anti-obesity actions (e.g., AMPK activation, gut microbiota modulation), BBR represents a paradigm shift toward accessible, low-cost therapies [10]. However, translational barriers persist, notably poor oral bioavailability (< 5%) and insufficient obesity-specific clinical validation.
Yue Kong et al. · Molecular Biomedicine · 2025

Why this rating

Based on preclinical evidence and safety record, but lacks robust clinical obesity data.

Source

Obesity: pathophysiology and therapeutic interventions

Yue Kong et al. · Molecular Biomedicine · 2025

DOI 10.1186/s43556-025-00264-9

narrative_reviewCited 44×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →